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Idiopathic epilepsies (IEs) are a group of disorders characterized by recurrent seizures in the absence of detectable brain lesions or meta-
bolic abnormalities. IEs include common disorders with a complex mode of inheritance and rare Mendelian traits suggesting the occur-
rence of several alleles with variable penetrance. We previously described a large family with a recessive form of idiopathic epilepsy,
named familial infantile myoclonic epilepsy (FIME), and mapped the disease locus on chromosome 16p13.3 by linkage analysis.
In the present study, we found that two compound heterozygous missense mutations (D147H and A509V) in TBC1D24, a gene of
unknown function, are responsible for FIME. In situ hybridization analysis revealed that Tbc1d24 is mainly expressed at the level of
the cerebral cortex and the hippocampus. By coimmunoprecipitation assay we found that TBC1D24 binds ARF6, a Ras-related family
of small GTPases regulating exo-endocytosis dynamics. The main recognized function of ARF6 in the nervous system is the regulation
of dendritic branching, spine formation, and axonal extension. TBC1D24 overexpression resulted in a significant increase in neurite
length and arborization and the FIME mutations significantly reverted this phenotype. In this study we identified a gene mutation
involved in autosomal-recessive idiopathic epilepsy, unveiled the involvement of ARF6-dependent molecular pathway in brain hyper-
excitability and seizures, and confirmed the emerging role of subtle cytoarchitectural alterations in the etiology of this group of common
epileptic disorders.Results and Discussion
Idiopathic epilepsies (IEs) are a group of disorders charac-
terized by recurrent seizures in the absence of detectable
brain lesions or metabolic abnormalities and affecting
about 0.4% of the general population. Epidemiological
studies highlighted the pivotal role of genetic factors in
the etiology of these conditions.1 IEs include common
disorders with a complex mode of inheritance and rare
Mendelian traits suggesting the occurrence of several
alleles with variable penetrance. The dissection of the
complex genetics underlying IEs represented so far a chal-
lenging task, and alleles conferring susceptibility to
seizures have not been identified yet. On the other hand,
the investigation of rare Mendelian traits highlighted
the critical role of genes encoding different ion channel
subunits, including voltage-gated and ligand-gated chan-
nels, and shed light into epileptogenic mechanisms
behind IEs.2,3 In addition, the identification of mutations
in LGI14 (ADLTE [MIM 600512]) and EFHC15 (EJM [MIM
254770]) in familial forms of IE underlying subtle defects
in embryonic or postnatal brain development provided
evidence that pathogenesis of IE is more composite.
In 2001, we described an autosomal-recessive early-onset
idiopathic generalized epilepsy in a large family from
Southern Italy characterized by myoclonic and generalized
tonic-clonic seizures, photosensitivity, normal neurolog-1Laboratory of Neurogenetics, Department of Neuroscience, Institute G. Gasli
mental Medicine, University of Genova and National Institute of Neuroscience
Italian Institute of Technology, Genoa, 16163, Italy; 4Laboratory of Genetics,
Mare, Napoli, 90100, Italy
6These authors contributed equally to this work
*Correspondence: afassio@unige.it (A.F.), federicozara@ospedale-gaslini.ge.it (F
DOI 10.1016/j.ajhg.2010.07.020. 2010 by The American Society of Human
The Americanical and mental development, and good response to treat-
ment (familial infantile myoclonic epilepsy, FIME [MIM
605021]) and mapped the FIME locus within a 3.4 cM
interval on chromosome 16p13.3 between markers
D16S3024 and D16S423.6,7
Toward the identification of the causative mutation, we
performed high-density SNP genotyping by pyrosequenc-
ing and refined the FIME critical region to 2 Mb between
rs35856 and rs9936111. The local Ethics Committee
approved the study and a signed informed consent was
obtained from family members participating to the
study. Haplotype analysis indicated the occurrence of two
distinct disease chromosomes suggestive of compound
heterozygous mutations and confirmed initial mapping
data (data not shown). The critical region contains 54
RefSeq genes, none of themwith a definite role in neuronal
excitability or epileptogenesis (Table S1 available online).
The systematic mutational screening of 34 genes in
two affected family members (III-1 and III-10) by Sanger
sequencing of amplified exonic sequences and flanking
intronic segments led to the identification of two com-
pound heterozygous missense mutations in TBC1D24
(c.439G>C [p.D147H]; c.1526C>T [p.A509V]) (Figures
1A and 1B). These variants are not included in the SNP
database and were not identified in 300 Italian controls.
No other candidate mutations emerged from the remain-
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Figure 1. Genetic Analysis of TBC1D24
(A)Pedigreeof the familywithFIMEandsegregationanalysisofTBC1D24mutations.Haplotypesareshownincoloredbars.The redandgreen
haplotypes cosegregate with c.1526C>Tand c.439G>C TBC1D24mutations, respectively. Affected patients are indicated by filled symbols.
(B) Electropherograms of c.439G>C and c.1526C>T mutations.
(C) Genomic organization and functional domains of human TBC1D24. Affected amino acids are highly conserved throughout evolution.
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Figure 2. Expression Analysis of TBC1D24
(A) RT-PCR showing the expression profile of TBC1D24 in various
human tissues. TBC1D24 is preferentially expressed in brain. Data
are represented as means5 SEM.
(B) RNA in situ hybridization on brain sections from 12-week-old
mouse shows that Tbc1d24 is abundantly expressed in the
neocortex (Cx) and hippocampus (Hp).
(C) High-magnification image of the cerebral cortex revealed
a higher expression of Tbc1d24 in deep cortical layers (V/VI)
compared to superficial layers (II-III).
(D) High-magnification image of hippocampus shows the highest
expression of Tbc1d24 in the CA3 region compared to the CA1
region and dentate gyrus (DG). Hb, hindbrain.available family members and confirmed that mutations
segregate from different branches and that all patients
affected by FIME are compound heterozygous carriers.
Moreover, none of the unaffected family members carry
both mutations. TBC1D24 encodes for a putative protein
of 553 amino acids of unknown function (accession IDs:
NM_020705.1 and NP_065756). BLASTP alignments indi-
cated that TBC1D24 has no significant homology with
other human proteins but is evolutionary conserved till
lower vertebrates (HomoloGene:27469).
TBC1D24 is characterized by a Tre2/Bub2/Cdc16 (TBC)
domain, shared by Rab GTPase-activating proteins (Rab-
GAPs) and a TLDc domain with no reported putative func-
tion, despite occurring in four additional human genes.8,9
The identified mutations affect two highly conserved
amino acids in TBC (D147H) and TLDc (A509V) domains
(Figure 1C). The combination of TBC and TLDc domains
is a unique feature among human proteins but it is found
in about 30 proteins of different species.
The expression profile of TBC1D24 was evaluated in
various human tissues by real-time PCR assay on an ABI
Prism 7500 Real-Time PCR Systems (Applied Biosystems)
with a TaqManMGB probe (assay ID; Hs00324855_m1,
Applied Biosystems) specific for human TBC1D24. Each
assay was carried out in triplicate, normalized to an endog-
enous reference (GAPDH [MIM 138400]), and expressed
relative to a calibrator sample as previously described.10
TBC1D24 is expressed in several human tissues, with the
highest level of expression in the brain (Figure 2A). To
further analyze the distribution of TBC1D24 within the
brain, RNA in situ hybridization was performed on coronal
sections from 12-week-old mouse brain via an anti-digox-
ygenin Tbc1d24 antisense oligonucleotide probe, as previ-
ously described.11 The Tbc1d24 signal was mainly detected
at the level of the cortex and the hippocampus (Figure 2B;
Figure S1). In the cerebral cortex, Tbc1d24 was expressed
through all layers, although more abundantly in layers
V/VI (Figure 2C); in the hippocampus, Tbc1d24 was mark-
edly expressed in the CA3 region and to a lower extent in
the CA1 region and dentate gyrus (Figure 2D). Moreover,
we evaluated the cortical expression of Tbc1d24 at different
embryonic stages (days 15.5 and 18.5) and found that
its expression increased during cortical development,
particularly in the internal part of the cortical plate and
in the subventricular zone (Figure S2).
Sequence analysis showed that the TBC domain of
TBC1D24 lacks critical residues conferring GAP properties
to most RabGAPs, particularly the ‘‘arginine finger’’ at
position 56 of the TBC domain consensus sequence
(PF00566).12 Three human TBC proteins missing the argi-
nine finger have been investigated and were all proven to
lack RabGAP activity (Table S2). Among these, USP6/
TRE17 and TBC1D3 have been shown to interact with
the small GTPase ADP ribosylation factor 6 (ARF6 [MIM
600464]).13,14 ARF6 is implicated in the regulation of
membrane trafficking between the plasma membrane
and the endocytic compartment through the activationThe Americanof the lipid-modifying enzymes phospholipase D and
phosphotidyl-inositol-4-phosphate 5-kinase.15
We therefore investigated the possible interaction
between TBC1D24 and ARF6 in COS7 cells (ATCC number
CRL-1651) overexpressing GFP-tagged TBC1D24 and HA-
tagged ARF6, in either its wild-type (WT), GDP-locked
(T27N), or GTP-locked (Q67L) form.16 When transiently
overexpressed in COS-7 cells and analyzed 36 hours
after transfection, GFP-TBC1D24 showed a predominant
cytoplasmatic localization (Figure 3A) and was partially
expressed at the plasma membrane where it colocalized
with coexpressed ARF6-HA (Figure 3B). For coimmunopre-
cipitation experiments, COS-7 cells were cotransfected
with GFP-TBC1D24 and ARF6-HA and lysed 36 hr after
transfection (lysis buffer: 50 mM Tris [pH 7.5], 150 mMJournal of Human Genetics 87, 365–370, September 10, 2010 367
Figure 3. TBC1D24 Is an ARF6-Interacting Protein
(A) Representative image of a COS-7 cell transfected with GFP-TBC1D24 and visualized 36 hr after transfection.
(B) Representative images of a COS-7 cell cotransfected with GFP-TBC1D24 and ARF6-HA and visualized 36 hr after transfection. HA
immunoreactivity was detected by HA antibody and Alexa546 conjugated secondary antibodies. The arrow in the merge panel shows
colocalization of overexpressed ARF6 and TBC1D24 at the plasma membrane.
Scale bars represent 20 mm.
(C) TBC1D24-WT, D147H, and A509V were cotransfected with HA-tagged wild-type (WT), T27N, or Q67L ARF6 in COS-7 cells and
immunoprecipitated (IP) with GFP antibody. Associated ARF6 (coIP) was detected by HA antibody (aHA) in retrospective western blot-
ting (WB). Wcl, whole cell lysate.NaCl, 0.1% sodium dodecyl sulfate, 1% Nonidet P40,
0.2 mM phenylmethylsulfonyl fluoride, 2 mg/ml pepstatin,
and 1 mg/ml leupeptin). GFP-TBC1D24 or ARF6-HA were
immunoprecipitated with anti-GFP or anti-HA polyclonal
antibodies (Invitrogen), respectively, and interacting
ARF6 or TBC1D24 were detected by retrospective immuno-
blotting with anti-HA or anti-GFP monoclonal antibodies
(Millipore). ARF-6 coimmunoprecipitated with TBC1D24
(Figure 3C) as well as TBC1D24 coimmunoprecipitated
with ARF6 (Figure S2). The intensity of the coimmunopre-
cipitated band increased in the presence of T27N-ARF6 and
decreased in the presence of Q67L-ARF6, suggesting
a GDP-dependent interaction (Figure 3C). When express-
ing TBC1D24 mutant forms, the interaction with ARF6
was significantly impaired by the D147H mutation and
preserved in the A509Vmutant (Figure 3C). These findings
suggest an involvement of the TBC domain in the interac-
tion with ARF6, as described for USP6,13 and reveal an
essential role of the aspartic acid 147 in mediating
TBC1D24-ARF6 interaction (Figure 3C).
The main function of ARF6 in the nervous system is the
regulation of dendritic branching, spine formation, and
axonal extension.17 To investigate the effect of TBC1D24
and FIME mutations in neuritogenesis, GFP-tagged wild-
type and mutant forms of TBC1D24 were transiently
expressed in primary cortical neurons prepared from
C57Bl6J mouse embryos as previously described18 and
neurite outgrowth and arborization were evaluated. Neu-
rons were plated at low density (100 cells/mm2), trans-
fected after 7 days in vitro (DIV) with lipofectamine trans-
fection reagent (Invitrogen), and analyzed at 9 DIV. For368 The American Journal of Human Genetics 87, 365–370, Septembanalysis, neurons were fixed in 4% PFA, 4% sucrose in
PBS and decorated with MAP2 antibody (Millipore) fol-
lowed by Alexa 594 secondary antibody to distinguish
dendrites from axons. For quantitative analysis of total
neurite length, neurites were traced and their total length
wasmeasured. The analysis of neurite arborization was per-
formed on 33 (GFP), 70 (WT), 43 (D147H), and 33 (A509V)
neurons from three independent preparations via the
Sholl analysis.19 Concentric circles with radii increasing
at regular steps of 10 mm were centered to the cell body
and the number of intersections was automatically evalu-
ated with the Image J Sholl analysis plug-in. TBC1D24
overexpression resulted in a marked increase in neurite
length and arborization compared to control, and the
effect was evident at the level of both axonal and den-
dritic compartments (Figures 4A–4D). As the inactive
ARF6 mutant (T27N) was shown to increase dendritic
branching20 and axonal elongation,21 our results are
consistent with a negative modulation of ARF6 function
by TBC1D24. The FIME mutations significantly reverted
this phenotype indicating a partial (D147H) or complete
(A509V) loss of function (Figures 4A–4D). Notably, A509V
mutation in the TLDc domain severely affected the ARF6-
dependent TBC1D24 function. The TLDc domain is highly
conserved through evolution from yeast to man, suggest-
ing a key biological function. In mammals this domain is
shared by genes involved in the response to oxidative
stress, such as OXR1 and Ncoa7b, but its specific role has
not been yet assessed.9
The identification of TBC1D24 mutations in patients
with epilepsy provides evidence of the involvement ofer 10, 2010
Figure 4. Functional Analysis of WT and Mutant
TBC1D24
(A) Representative images of mouse cortical neurons trans-
fected at 6 DIV with either GFP, GFP-TBC1D24-wt (WT),
GFP-TBC1D24-D147H (D147H), or GFP-TBC1D24-A509V
(A509V) and visualized 36 hr after transfection. Scale bar
represents 50 mm.
(B and C) Overexpression of TBC1D24 provoked a massive
increase in neurite length (B) and branching (C), whereas
overexpression of its epileptogenic mutants (i.e., D147H
and A509V) reverted this phenotype.
(D) Quantitative analysis of neurite (total), dendrite, or
axon length in 33 cells for each genotype. Dendrites
and axons were distinguished by MAP2 labeling and/or
morphology. Data expressed as means 5 SEM and com-
pared via one-way analysis of variance (ANOVA, B and C)
or repeated-measures ANOVA (D) followed by the Bonferro-
ni’s multiple comparison test. ***p < 0.0001, **p < 0.001
versus GFP; p < 0.0001, p < 0.001, p < 0.01 versus
GFP-TBC1D24-wt.the ARF6-dependent molecular pathway in the generation
of brain hyperexcitability and seizures. ARF6 has been
shown to participate in several processes of neuronal
development and plasticity by regulating axonal elonga-
tion and branching,20 dendrite arborization,21 and exo-
endocytic cycling of synaptic vesicles.22 In addition, recent
evidence points out a role for ARF6 in spine maturation
and stability23 and in the control of AMPA receptor inter-
nalization during long-term depression,24 both processes
implicated in the modulation of brain excitability.
The identification of TBC1D24 mutations in epileptic
patients together with its predominant expression in crit-
ical epileptogenic brain areas also highlights a fundamental
role of this protein in the regulation of neuronal network
excitability. Moreover, the evidence that epileptogenic
mutations affected neurite outgrowth and arborization
suggests a critical role of TBC1D24 in developmentally
regulated events essential for the morphological and func-
tional maturation of neuronal circuitry. The increasing
expression of TBC1D24 during embryogenesis in the
cortex further strengthens this hypothesis.
Compelling evidence indicates that morpho-functional
changes underlie epileptogenesis in different epileptic
disorders with congenital or acquired gross structural brain
abnormalities, such as defects in neuronal migration
(e.g., lissencephaly or epileptic heterotopias), proliferation
(e.g., tuberous sclerosis), and degeneration (e.g., progres-
sive myoclonus epilepsies).25
However, recent data highlight the role of develop-
mental dynamics also in idiopathic epilepsy and dis-
close novel mechanisms underlying brain hyperexcit-
ability. LGI1,4 mutated in the autosomal-dominantThe American Journallateral temporal lobe epilepsy, regulates the func-
tional maturation and structural pruning of gluta-
matergic synapses during postnatal development,
and its impairment markedly increases excitatory
synaptic trasmission. EFHC1,5 which is involved in
juvenile myoclonic epilepsy, one of the mostfrequent forms of idiopathic generalized epilepsy, interacts
with microtubules to regulate cell division and cortical
development and its loss disrupts radial migration of
projection neurons in the developing rat neocortex.
In this study, we identified TBC1D24 as a gene involved
in autosomal-recessive idiopathic epilepsy and showed
that its protein product is a binding partner of ARF6
involved in neurite outgrowth. We unveiled the involve-
ment of ARF6-dependent molecular pathway in brain
hyperexcitability and seizures and confirmed the emerging
role of subtle cytoarchitectural alterations in the etiology
of this group of common epileptic disorders.Supplemental Data
Supplemental Data include two figures and two tables can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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